Celgene Corp. (CELG)

65.93
2.20 3.20
NASDAQ : Health Technology
Prev Close 68.13
Open 68.49
Day Low/High 66.25 / 68.49
52 Wk Low/High 66.62 / 110.20
Volume 3.69M
Avg Volume 5.81M
Exchange NASDAQ
Shares Outstanding 699.25M
Market Cap 48.77B
EPS 3.80
P/E Ratio 17.31
Div & Yield N.A. (N.A)

Latest News

A Way to Exploit Algorithm-Induced Market Swings When Trading Biotech Issues

A Way to Exploit Algorithm-Induced Market Swings When Trading Biotech Issues

It can be disturbing to see various names lose value quickly on no news, but here is a method to take advantage of such moves.

Celgene Corporation Announces Initial Clinical Data From Ongoing Phase 1/2 Evolve Trial With Anti-BCMA CAR T Therapy JCARH125 In Relapsed/Refractory Multiple Myeloma At ASH 2018

Celgene Corporation Announces Initial Clinical Data From Ongoing Phase 1/2 Evolve Trial With Anti-BCMA CAR T Therapy JCARH125 In Relapsed/Refractory Multiple Myeloma At ASH 2018

Celgene Corporation (NASDAQ:CELG) today announced initial safety data from its ongoing proof-of-concept trial of JCARH125 in patients with relapsed/refractory multiple myeloma.

Celgene Corporation Announces Results Of AUGMENT Evaluating REVLIMID® In Combination With Rituximab (R2) In Patients With Relapsed/Refractory Indolent Lymphoma At ASH 2018

Celgene Corporation Announces Results Of AUGMENT Evaluating REVLIMID® In Combination With Rituximab (R2) In Patients With Relapsed/Refractory Indolent Lymphoma At ASH 2018

Celgene Corporation (NASDAQ: CELG) today announced results of the phase 3 AUGMENT study, which showed that REVLIMID ® (lenalidomide) in combination with rituximab (R 2) demonstrated superior progression-free survival (PFS) in patients with...

Bluebird Bio And Celgene Corporation Present Initial Data From Ongoing Phase 1 Clinical Study Of Next-Generation Anti-BCMA CAR T Cell Therapy Bb21217 In Patients With Relapsed/Refractory Multiple Myeloma At ASH Annual Meeting

Bluebird Bio And Celgene Corporation Present Initial Data From Ongoing Phase 1 Clinical Study Of Next-Generation Anti-BCMA CAR T Cell Therapy Bb21217 In Patients With Relapsed/Refractory Multiple Myeloma At ASH Annual Meeting

bluebird bio, Inc. (Nasdaq:BLUE) and Celgene Corporation (NASDAQ:CELG) announced initial data from the ongoing Phase 1 clinical study of bb21217 (CRB-402), an investigational next-generation anti-BCMA CAR T cell therapy being studied in patients with...

Celgene Corporation And Acceleron Pharma Announce Results Of The Phase 3 MEDALIST Trial Evaluating Luspatercept In Patients With Myelodysplastic Syndromes At The ASH 2018 Plenary Session

Celgene Corporation And Acceleron Pharma Announce Results Of The Phase 3 MEDALIST Trial Evaluating Luspatercept In Patients With Myelodysplastic Syndromes At The ASH 2018 Plenary Session

Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced results from the pivotal, phase 3 MEDALIST trial evaluating the efficacy and safety of investigational luspatercept to treat patients with ring sideroblast (RS+)...

Celgene Corporation Announces Initial Phase 1/2 Liso-cel Data In Patients With Relapsed/Refractory CLL, Including Those With High-Risk Disease, Previously Treated With Ibrutinib, At ASH 2018

Celgene Corporation Announces Initial Phase 1/2 Liso-cel Data In Patients With Relapsed/Refractory CLL, Including Those With High-Risk Disease, Previously Treated With Ibrutinib, At ASH 2018

Celgene Corporation (NASDAQ: CELG) today announced initial data from the dose-escalation part of an ongoing, open-label multicenter phase 1/2 study of investigational lisocabtagene maraleucel (liso-cel; JCAR017) in patients with relapsed/refractory...

Celgene Corporation And Acceleron Pharma Announce Results Of The Phase 3 BELIEVE Trial Evaluating Luspatercept In Adult Patients With Beta-Thalassemia At ASH 2018

Celgene Corporation And Acceleron Pharma Announce Results Of The Phase 3 BELIEVE Trial Evaluating Luspatercept In Adult Patients With Beta-Thalassemia At ASH 2018

Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced results from a pivotal, phase 3 trial (BELIEVE) evaluating the safety and efficacy of luspatercept for the treatment of adults with beta-thalassemia-associated...

2 Small Biotech Stocks That Insiders Are Buying

2 Small Biotech Stocks That Insiders Are Buying

Both names looked poised to go higher as soon as sentiment around the small biotech sector improves.

Celgene Is Showing Us a Couple of Interesting Bullish Divergences

Celgene Is Showing Us a Couple of Interesting Bullish Divergences

Celgene could be at a temporary low or it could be starting a new base pattern.

Celgene Corporation And Bluebird Bio Complete Enrollment Of Pivotal KarMMa Study Of Anti-BCMA Car T Cell Therapy Bb2121 In Patients With Relapsed And Refractory Multiple Myeloma

Celgene Corporation And Bluebird Bio Complete Enrollment Of Pivotal KarMMa Study Of Anti-BCMA Car T Cell Therapy Bb2121 In Patients With Relapsed And Refractory Multiple Myeloma

Celgene Corporation (Nasdaq: CELG) and bluebird bio, Inc. (Nasdaq: BLUE) today announced the completion of enrollment for the KarMMa pivotal study of bb2121, the companies' lead investigational anti-BCMA CAR T cell therapy candidate for patients with...

Classic Bear-Market Rally: Cramer's 'Mad Money' Recap (Monday 11/26/18)

Classic Bear-Market Rally: Cramer's 'Mad Money' Recap (Monday 11/26/18)

What comes next? Anything concrete to justify this rally? Sorry, says Jim Cramer. It's just a reprieve, not a sustainable turnaround.

Jim Cramer: I Can't Believe How Badly Many Huge, Important Stocks Have Performed

Jim Cramer: I Can't Believe How Badly Many Huge, Important Stocks Have Performed

I tire of hearing that there has been a correction.

Here's a Handful of Ways to Navigate Biotech's Choppy Seas

Here's a Handful of Ways to Navigate Biotech's Choppy Seas

Biotech ETFs could mitigate risk amid the sector's volatility, and names such as Exelixis, ANI Pharmaceuticals and Progenics hold promise.

Here's How I'm Playing Biotech Now

Here's How I'm Playing Biotech Now

I continue to deploy 'dry powder' into the biotech sector on dips using Buy-Write option strategies.

Lyfebulb Partners With Celgene To Inspire Patient-Driven Innovation In The Management Of Multiple Sclerosis

Lyfebulb Partners With Celgene To Inspire Patient-Driven Innovation In The Management Of Multiple Sclerosis

NEW YORK, Nov. 14, 2018 /PRNewswire/ -- Lyfebulb, a chronic disease-focused, patient-empowerment platform that connects patients with industry and investors to support user-driven innovation, announced it is joining forces with Celgene (NASDAQ: CELG) to...

Gridlock and Economic Slowing: Cramer's 'Mad Money' Recap (Tuesday 11/6/18)

Gridlock and Economic Slowing: Cramer's 'Mad Money' Recap (Tuesday 11/6/18)

Jim Cramer explains his post-election play book: Growth stocks may be the way to go.

Canada Goose, Celgene, BlackRock: 'Mad Money' Lightning Round

Canada Goose, Celgene, BlackRock: 'Mad Money' Lightning Round

Jim Cramer weighs in on Canada Goose, Celgene, BlackRock, Nio, Hospitality Property Trust, Activision Blizzard and more.

Eli Lilly's Elanco Offload Offers Acquisition Flexibility

Eli Lilly's Elanco Offload Offers Acquisition Flexibility

Eli Lilly's confirmation of acquisition action could make pharmaceuticals an attractive investment space.

Celgene Corporation To Webcast At Upcoming Investor Events

Celgene Corporation To Webcast At Upcoming Investor Events

Celgene Corporation (NASDAQ:CELG) plans to present at two upcoming investor events where Celgene management will provide an overview of the Company.

Results From More Than 100 Abstracts Highlighting Celgene Pipeline Compounds And Therapies To Be Presented At The American Society Of Hematology Annual Meeting (ASH)

Results From More Than 100 Abstracts Highlighting Celgene Pipeline Compounds And Therapies To Be Presented At The American Society Of Hematology Annual Meeting (ASH)

Celgene Corporation (NASDAQ:CELG) today announced that data from more than 100 abstracts, including a study being featured as a plenary presentation and more than 40 selected for oral presentations, evaluating Celgene investigational agents and...

Here Are 9 Takeaways From Last Night's Meltdown: Market Recon

Here Are 9 Takeaways From Last Night's Meltdown: Market Recon

It becomes difficult for me to tell you where to run in these markets...

Celgene Reports Third Quarter 2018 Operating And Financial Results

Celgene Reports Third Quarter 2018 Operating And Financial Results

Celgene Corporation (NASDAQ:CELG) reported net product sales of $3,890 million for the third quarter of 2018, an 18 percent increase from the same period in 2017.

Lululemon Athletica, Celgene, McDonald's: 'Mad Money' Lightning Round

Lululemon Athletica, Celgene, McDonald's: 'Mad Money' Lightning Round

Jim Cramer takes a closer look at Lululemon Athletica, Celgene, McDonald's, Red Robin Gourmet Burgers, Apple Hospitality REIT.

Tariffs and the Fed: Cramer's 'Mad Money' Recap (Wednesday 10/24/18)

Tariffs and the Fed: Cramer's 'Mad Money' Recap (Wednesday 10/24/18)

This is serious: The market is ignoring legitimate, positive earnings, says Jim Cramer, and tariffs and rates are the culprits.

Why Investors Should Favor Smaller Biotech Companies

Why Investors Should Favor Smaller Biotech Companies

Small and mid-cap biotech firms are driving innovation in the sector. Experts explain why investors should take notice.

(Photo: Business Wire)

(Photo: Business Wire)

TV host and fashion journalist Louise Roe launches the INSIDE PERSPECTIVE campaign with Celgene Corporation (NASDAQ: CELG) and Otezla ® (apremilast), and for the first time, shares her inside story with psoriasis, a condition she has been living with for...

REVLIMID® (lenalidomide) Demonstrated A Significant Improvement In Progression-Free Survival (PFS) Compared With Observation In A Randomized Study In Patients With Smoldering Multiple Myeloma

REVLIMID® (lenalidomide) Demonstrated A Significant Improvement In Progression-Free Survival (PFS) Compared With Observation In A Randomized Study In Patients With Smoldering Multiple Myeloma

Celgene Corporation (NASDAQ: CELG) today announced results from an open-label phase II/III National Clinical Trials Network (NCTN) study led by the ECOG-ACRIN Cancer Research Group and sponsored by the National Cancer Institute (NCI), part of the National...

Celgene Corporation Announces Appointment Of Dr. Alise Reicin To President, Global Clinical Development

Celgene Corporation Announces Appointment Of Dr. Alise Reicin To President, Global Clinical Development

Celgene Corporation (NASDAQ:CELG) today announced the appointment of Dr. Alise Reicin to President, Global Clinical Development, reporting to Mark J.

TheStreet Quant Rating: C (Hold)